Request a sponsored account
If your institution has a site license, you may be eligible for a sponsored account.
Enter your organization-affiliated email address below to request or renew your sponsored account.
Enter your organization-affiliated email address below to request or renew your sponsored account.
Latest Stories
News Analysis
Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions.
Clinical
Following last month’s dismissal of the securities class action complaint against Illumina Inc. and its former spinoff company, GRAIL, the plaintiffs have refiled an amended complaint, keeping the action alive.
The Friends of Cancer Research annual meeting, to be held Nov. 4 in Washington, DC, will focus on three questions facing the field of oncology clinical trial design.
Trials & Tribulations
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
Cancer Policy
The federal government shutdown is entering its fifth week, and funding delays are now directly affecting the healthcare system.
Cancer Policy
Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, often called “the voice of the CDC,” now has an rival publication.
Cancer Policy
Last week, President Donald Trump announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of some fertility drugs used for in-vitro fertilization, in exchange for a three-year reprieve on some of the tariffs levied on pharmaceutical imports (The Cancer Letter, Oct. 24, 2025).
In Brief
Jonathan D. Licht was named president and chief scientific officer of the Van Andel Institute. Licht will begin his new role in early 2026.
In Brief
The University of Illinois College of Medicine and Cook County Health have expanded their collaborative partnership that began in 2021.
In Brief
Vinai GondiBridget KoontzPriya RastogiLisa LenrowNRG Oncology, an NCI National Clinical Trials Network group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple committees.
In Brief
Eytan Ruppin, a data scientist who works with AI-based methods for predicting individual patients’ response to cancer therapies, has joined Cedars-Sinai Cancer as deputy director of the Translational Research Institute. He will also serve as director of Integrative Data Sciences in the Division of Surgical Research.
In Brief
The University of Texas MD Anderson Cancer Center has awarded Kimberly Vanderhorst and Terri Lynn Dunn the 2025 Brown Foundation Award for Excellence in Oncology Nursing.
In Brief
Northwell Cancer Institute has partnered with Cancer Hope Network to provide personalized peer mentorship for cancer patients by connecting them with specially trained survivors who have navigated similar cancer diagnoses.
Clinical Roundup
Positive topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma were recently reported.
Clinical Roundup
Using intraoperative radiation to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins have been able to reduce the recurrence rate around the pancreas to 5%.
Clinical Roundup
Federally funded research in mice showed that neurons regulate osteosarcoma progression, suggesting that inhibiting nerve signaling might improve patient outcomes.
Clinical Roundup
Scientists face limitations in determining the results of drug effectiveness, as well as ensuring even distribution among all cancer cells because of the highly compact nature of tumors. Researchers are working to change that by giving chemotherapy drugs a kind of chemical “signal” to track them inside cells.
Clinical Roundup
Mayo Clinic researchers have discovered why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates.
Clinical Roundup
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that “first-responder” immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.
Drugs & Targets
In a new draft guidance, FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical testing.
Drugs & Targets
The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.
Podcast
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
Regulatory News
New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.
Kyle Walsh, a brain tumor expert at the Duke Cancer Institute, was named director of the National Institute of Environmental Health Sciences.
Clinical
Recent results from the PATHFINDER 2 study showed that the addition of GRAIL’s multi-cancer detection test to standard screening led to a seven-fold increase in cancers detected within a year, the company said.
The National Academy of Medicine announced the election of 90 regular members and 10 international members during its annual meeting Oct. 18-20.
Trials & Tribulations
Testing of chemicals for potential cancer causation (carcinogenesis) has long been a successful disease-prevention initiative of the highest priority.
Cancer Policy
NCI officials were notably absent from the annual meeting of the Association of American Cancer Institutes and the Cancer Center Administrators Forum in Washington, DC, due to the government shutdown that started on Oct. 1.
Cancer Policy
Scientists, health care professionals, and supporters will take to the streets on Nov. 5, calling for Congress to remove Robert F. Kennedy Jr. from his position as Secretary of Health and Human Services.
Cancer Policy
Earlier this year, FDA announced that it would be initiating a voucher program aimed at accelerating review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, June 20, 2025).
Cancer Policy
A court filing by Thomas Nagy Jr., deputy assistant secretary for Human Resources and chief human capital officer at HHS, claims that his department can proceed with the 982 RIFs it issued two weeks ago, despite a judge’s temporary order freezing the notices issued by two dozen federal agencies since the government shutdown that began on Oct 1.
Cancer Policy
With the start of open enrollment less than one week away, millions of Americans are getting their first look at the sharp increases many will pay next year if Congress fails to extend the enhanced premium tax credits that have expanded healthcare access to over 13 million people since 2021.
Cancer Policy
President Donald Trump has announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of certain fertility drugs used for in-vitro fertilization, or IVF.
In Brief
Alan KormanAviv RegevJeffrey C. RathmellThe Cancer Research Institute has announced the 2025 recipients of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology and the Frederick W. Alt Award for New Discoveries in Immunology.
In Brief
The American College of Radiology has announced the 2026 Gold Medalists and Honorary Fellows Recipients to be recognized during ACR 2026, the college’s annual meeting in Washington, DC, May 2-6, 2026.
Clinical Roundup
Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.
Clinical Roundup
Data from the phase III ASCENT-03 study demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival for Trodelvy (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors.
Clinical Roundup
Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival in patients with a high risk of disease recurrence, according to results from DESTINY-Breast05 phase III trial.
Clinical Roundup
Positive results from the DESTINY-Breast11 phase III trial showed Enhertu (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab, and pertuzumab in the neoadjuvant setting demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response rate.
Clinical Roundup
Merck presented long-term data highlighting the sustained survival benefits of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer at the European Society for Medical Oncology Congress 2025.
Clinical Roundup
Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk of event-free survival events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer who are not eligible for or declined cisplatin-based chemotherapy, according to phase III KEYNOTE-905/EV-303 trial data.
Clinical Roundup
Two years of adjuvant Verzenio (abemaciclib) plus endocrine therapy reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival and distant relapse-free survival, in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, according to the primary overall survival analysis of the phase III monarchE trial.
Clinical Roundup
Positive results from the POTOMAC phase III trial showed adding one year of treatment with Imfinzi (durvalumab) to BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.
Clinical Roundup
Perioperative treatment with Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival versus chemotherapy alone, according to MATTERHORN phase III trial results.
Clinical Roundup
The combination of Tecvayli (teclistamab-cqyv), a bispecific T-cell engager antibody therapy, and Darzalex Faspro (daratumumab and hyaluronidase-fihj), a subcutaneous CD38-directed antibody, met the primary endpoint of progression-free survival and the results were statistically significant and superior to standard of care in relapsed/refractory multiple myeloma who received one to three prior lines of therapy, according to data from the phase III MajesTEC-3 study. This was compared to the investigator’s choice of Darzalex Faspro, pomalidomide, and dexamethasone or Darzalex Faspro, bortezomib, and dexamethasone.
Clinical Roundup
GammaTile showed superiority in the primary endpoint of the study. Patients who received GammaTile lived longer without tumor regrowth, reducing the risk of either tumor recurrence or death by 50% reduction compared to standard of care, according to interim results from the ROADS clinical trial, which evaluated GammaTile versus standard of care in patients with operable, newly diagnosed brain metastases.
Clinical Roundup
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.
Drugs & Targets
FDA approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Drugs & Targets
Regeneron Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Libtayo (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation. Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells.
Podcast
“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.
Trials & Tribulations
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
Regulatory News
Bowing to the growing animal rights movement, FDA and NIH have made policy changes to discourage animal testing, instead favoring alternative research models.
Guest Editorial
Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
When the idea of looking at cancer center funding and the cancer burden of cancer center catchment areas came to us in the summer of 2024, we lived in a different context.
Sponsored
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations.
Cancer Policy
Millions of Americans with Affordable Care Act marketplace health insurance will face higher costs next year if Congress doesn’t extend enhanced premium tax credits that have made the plans more affordable for low- and middle-income enrollees.
Cancer Policy
A federal judge issued a temporary restraining order on Oct. 15, ordering the Trump administration to reverse the wave of layoffs that the administration is using as a pressure tactic intended to force the Democrats to accept cuts to popular health programs and reopen the government.
Cancer Policy
As of Oct. 1, Medicare no longer covers telehealth visits.
In Brief
Ross L. Levine was named chief scientific officer at Memorial Sloan Kettering Cancer Center.
In Brief
Robert G. UzzoJonathan ChernoffDavid WiestJoel HelmkeRobert G. Uzzo’s role as president and CEO of Fox Chase Cancer Center will now extend beyond the American Oncologic Hospital and include the Institute for Cancer Research, uniting Fox Chase’s dual missions of cancer care and research, officials said.
In Brief
Alison LorenAdam CukerMikkael SekeresThe American Society of Hematology announced the election of three new members to its executive committee for terms starting after the 2025 ASH Annual Meeting on Dec. 6-9 in Orlando.
In Brief
Armando E. Giuliano will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9-12 at the Henry B. Gonzalez Convention Center in San Antonio.
In Brief
The Tampa General Hospital Cancer Institute has been accepted into the Association of American Cancer Institutes, a recognition of its commitment to excellence in cancer research, treatment, education, and community outreach and engagement.
In Brief
CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has entered into a collaborative partnership with Einstein Hospital Israelita in Sao Paulo, Brazil, aimed at accelerating the adoption of cell therapy in Brazil and all of Latin America.
In Brief
The START Center for Cancer Research, the world’s largest community-based network specializing in early-phase oncology clinical trials, together with HM Hospitales, announced the launch of a pediatric onco-hematology clinical research unit at HM Montepríncipe University Hospital in Madrid.
Clinical Roundup
The phase III HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor Tukysa in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer has met its primary endpoint.
Clinical Roundup
Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial.
Clinical Roundup
AccessHope has unveiled new research that demonstrates how remote expert oncology opinions can meaningfully bridge socioeconomic and geographic barriers to facilitate optimal cancer care.
Clinical Roundup
Mayo Clinic administered an investigational radioactive medicine to a patient with hepatocellular carcinoma.
Clinical Roundup
Cancer is a challenging enough diagnosis, but many patients are dealt a second blow, even as they heal: chemo brain.
Clinical Roundup
Researchers at the UC San Diego School of Medicine engineered a new anti-αvβ3 antibody that activates macrophages—a type of immune cell already abundant in advanced αvβ3+ tumors—and were able to trigger anti-tumor responses in both patient tumor samples and in mouse models.
Clinical Roundup
Elevated calcium levels in the blood—a complication of kidney cancers known as hypercalcemia—may be successfully treated with HIF-2α inhibitors developed by UT Southwestern Medical Center.
Clinical Roundup
Taking brain cancer biopsies over time revealed positive changes to the tumor microenvironment, even when traditional imaging scans showed the tumor getting worse, according to a multi-institutional study from the Accelerating GBM Therapies Through Serial Biopsies TeamLab, led by investigators from the Mass General Brigham Cancer Institute.
Clinical Roundup
A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.
Drugs & Targets
FDA has received reports of immune effector cell-associated enterocolitis in patients who received treatment with Carvykti.
Drugs & Targets
Tempus AI was selected by the Advanced Research Projects Agency for Health to provide testing and contract research organization services in support of the agency’s Advanced Analysis for Precision Cancer Therapy program.
Drugs & Targets
Algen Biotechnologies and AstraZeneca are entering into a multi-target research collaboration to advance AI-powered drug discovery in immunology.
Podcast
In honor of Hispanic Heritage Month, this week’s episode of The Cancer Letter Podcast features three oncology leaders whose research focuses on identifying and solving health disparities specifically in the Latinx community.
The Directors
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
Guest Editorial
Cancer care is evolving at an unprecedented pace. Practitioners feel the mounting pressures daily: rising cancer rates—particularly in younger patients—a growing population of older cancer survivors, rapid growth in new care and treatment options, and navigating heightened fiscal constraints and uncertainty.
In 1988, Frank McCormick learned with the rest of the field that more than 90% of patients with pancreatic cancer have a mutation in the Kirsten rat sarcoma viral gene.
Guest Editorial
As every non-profit organization knows, it is our obligation to be purpose-driven. Most NPO founders and the people who work for them have been thrown into this space as a result of life experiences. It is our passion rather than a job to simply collect a paycheck.
Cancer Policy
A report by the American Society of Clinical Oncology points to a growing challenge in cancer care access driven by a widening gap between the number of available oncologists and increasing patient demand.
Cancer Policy
President Donald Trump had threatened pharmaceutical companies with a 100% tariff, with an ultimatum set for Oct. 1.
Cancer Policy
Jim O’Neill, acting director of the Centers for Disease Control and Prevention, announced that he has signed off on a slew of recommendations that change the childhood vaccination schedule.
Cancer Policy
NIH has published a policy that prohibits U.S. researchers and NIH grant recipients working with human biospecimens to share this data with “countries of concern.” That list includes China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela.
Cancer Policy
Governor Gavin Newsom Oct. 6 signed into law SB 351—a piece of legislation that prohibits hedge fund and private equity groups from interfering with the medical decisionmaking of physicians and their patients.
Cancer Policy
United for Medical Research conducted a report surveying patients and researchers on why NIH, and NIH funding matters to them.
In Brief
Cornelia UlrichDiane M. SimeoneBarry P. SleckmanCornelia Ulrich was selected to serve as vice president/president-elect of the Association of American Cancer Institute’s board of directors. Ulrich is chief scientific officer and executive director of the Comprehensive Cancer Center at Huntsman Cancer Institute at the University of Utah.
In Brief
Paul Boutros was named director of the NCI-designated Basic Laboratory Cancer Center at Sanford Burnham Prebys Medical Discovery Institute.
In Brief
NCI has awarded a five-year, $11.2 million Cancer Health Disparities Specialized Program of Research Excellence in Endometrial Cancer grant to Victoria Bae-Jump and Hazel Nichols at the University of North Carolina Lineberger Comprehensive Cancer Center.
In Brief
Ruth Rechis was named chief prevention officer the Cancer Prevention & Research Institute of Texas.
In Brief
Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.
In Brief
The University of Kansas Cancer Center is poised to be part of a deal called “Name, Image and Likeness” that will benefit cancer research and engage KU basketball student-athletes.
Clinical Roundup
Positive high-level results from the Tropion-Breast02 phase III trial showed Datroway (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.
Clinical Roundup
Men with intermediate-risk prostate cancer can receive a complete course of radiation in just five treatments—rather than the typical 20 to 28—while maintaining excellent cancer control and improving quality of life, according to results of an international phase III trial conducted by Rodney J. Ellis.
Clinical Roundup
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at the Ohio State University Comprehensive Cancer Center is using artificial intelligence to devise new ways of predicting which patients will develop an aggressive and difficult-to-detect form of breast cancer called lobular cancer, which represents one in every 10 breast cancers diagnosed in the United States.
Clinical Roundup
Researchers have refined a powerful DNA sequencing tool that can uncover hidden mutations that occur naturally in our bodies as we age. In the largest study to date, they have used the tool to provide insights into the earliest steps of cancer development and the role of mutations in healthy tissue.
Clinical Roundup
Using cell cultures and animal models, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC showed that next-generation CAR T cells can safely and effectively shrink solid tumors.
Clinical Roundup
Cell and gene therapies are steadily becoming more available to patients, but are still facing systemic hurdles slowing widespread adoption, according to the second annual 2025 “Cell and Gene Therapy Report: Advancing the Future of Medicine,” published by InspiroGene by McKesson.
The report draws on new insights from research with physicians and payers, an updated analysis of the U.S. CGT pipeline, and an analysis of all the U.S. sites of care where CGTs are administered.
The report showcases a newly refreshed interactive map of qualified CGT treatment centers nationwide, along with exclusive insights from leading industry experts.
Key findings include:
- Providers are gaining experience, but barriers persist. According to a double-blinded nationwide survey of more than 125 oncologists, familiarity with CGTs is growing—60% say they are very familiar with CGTs vs 55% in 2024, and the average number of patients treated has risen from 17 to 25 annually. However, access challenges remain entrenched. Two-thirds of oncologists still view CGTs as “largely unproven,” and 66% say their patients view CGTs as “too experimental or risky.” Community-based oncologists navigate particularly complex challenges around site readiness and reimbursement.
- Payers recognize CGT’s potential but demand more evidence to approve reimbursement. While 80% of interviewed payers believe CGTs are safe and effective, they remain skeptical about high upfront costs and limited long-term data. 60% of payers say innovative payment models could mitigate the risks of CGTs, but cite the need for easy-to-measure, clinically relevant endpoints to make these models effective.
- Expansion into the community is happening, slowly. The number of qualified treatment centers in the U.S. is flat from 2024 to 2025, underscoring the disappointingly slow pace at which CGT care is migrating into community settings.
- The CGT pipeline continues to expand rapidly. A total of 178 oncology-focused drug candidates entered the late-stage pipeline in the past year alone, signaling continued momentum in cancer research. Beyond oncology, promising early results are emerging in lupus, diabetes and heart failure, reflecting CGT’s growing potential to benefit broader patient populations.
Clinical Roundup
The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial—a large-scale, phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.
